Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H17N |
| Molecular Weight | 235.3236 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C=CCN1CC2=CC=CC=C2C3=CC=CC=C3C1
InChI
InChIKey=NYGHGTMKALXFIA-UHFFFAOYSA-N
InChI=1S/C17H17N/c1-2-11-18-12-14-7-3-5-9-16(14)17-10-6-4-8-15(17)13-18/h2-10H,1,11-13H2
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Furter investigations on the interaction between alpha-adrenoceptor antagonists and the central hypotensive effect of clonidine in rats, rabbits and dogs. | 1980-07 |
|
| An in vivo model for investigating alpha 1- and alpha 2-receptors in the CNS: studies with mianserin. | 1979-11 |
|
| DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. | 1979-02 |
|
| Clinical effects of azapetine (ilidar) on peripheral arterial disease. | 1956-06-30 |
|
| Clinical trial of ilidar; a new dibenzazepine adrenergic blocking drug, in the treatment of peripheral vascular diseases and miscellaneous complaints. | 1954-09 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC04AX30
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
||
|
WHO-ATC |
C04AX30
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2110596
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
146-36-1
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
265
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
100000077661
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
SUB12970MIG
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
DTXSID50163250
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
8966
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
AZAPETINE
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
C83540
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
205-667-3
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
C004448
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
9TTR0UA2KC
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY | |||
|
DB13727
Created by
admin on Mon Mar 31 18:32:00 GMT 2025 , Edited by admin on Mon Mar 31 18:32:00 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)